Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Study Overview

This research study is studying a combination of drugs as a possible treatment for rare genitourinary malignancies.

-The names of the study drugs involved in this study are:

  • Nivolumab
  • Ipilimumab

Study Description

A phase II study of nivolumab combined with ipilimumab for patients with advanced rare genitourinary tumors

  • Identifier: NCT03333616
  • Protocol Number: 17-423
  • Principal Investigator: Glenn Bubley

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

If you need assistance finding a study or if you have any questions, call us at 617-667-7000